Press Releases

Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010 | 2009
DateTitle 
10/22/14Alkermes to Host Conference Call to Discuss Third Quarter 2014 Financial ResultsPrinter Friendly Version
10/22/14Alkermes’ New Drug Application for Aripiprazole Lauroxil for Treatment of Schizophrenia Accepted for Filing by U.S. FDAPrinter Friendly Version
09/03/14Alkermes Announces Completion of Patient Enrollment in Phase 2 Study of ALKS 3831, a Novel, Broad-Spectrum Oral AntipsychoticPrinter Friendly Version
09/02/14Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare ConferencePrinter Friendly Version
08/26/14Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 7106 for Treatment of PainPrinter Friendly Version
08/25/14Alkermes Submits New Drug Application to FDA for Aripiprazole Lauroxil for Treatment of SchizophreniaPrinter Friendly Version
07/31/14Alkermes plc Reports Second Quarter 2014 Financial ResultsPrinter Friendly Version
07/30/14Alkermes Announces Initiation of FORWARD-5 Clinical Study of ALKS 5461 For Treatment of Major Depressive DisorderPrinter Friendly Version
07/24/14Alkermes to Host Conference Call to Discuss Second Quarter 2014 Financial ResultsPrinter Friendly Version
07/17/14Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple SclerosisPrinter Friendly Version
07/09/14Alkermes Announces Notices of Allowance for U.S. Patents for Four CNS Pipeline CandidatesPrinter Friendly Version
06/18/14Alkermes Presents Phase 3 Data From Successful Pivotal Study of Aripiprazole Lauroxil for Treatment of Schizophrenia at ASCP Annual MeetingPrinter Friendly Version
06/10/14Alkermes Announces Initiation of FORWARD-3 and FORWARD-4 Efficacy Studies in Pivotal Program for ALKS 5461 for Treatment of Major Depressive DisorderPrinter Friendly Version
06/03/14Alkermes to Present Data on New Medicines in Development for Schizophrenia and Depression at Upcoming American Society of Clinical Psychopharmacology Annual MeetingPrinter Friendly Version
06/02/14Alkermes Announces Initiation of Second Phase 2 Clinical Study of ALKS 3831, a Novel Broad-Spectrum Oral AntipsychoticPrinter Friendly Version
05/27/14Alkermes’ Corporate Presentation to be Webcast at Two Upcoming ConferencesPrinter Friendly Version
05/12/14Alkermes’ Corporate Presentation to be Webcast at the UBS Global Healthcare ConferencePrinter Friendly Version
04/30/14Alkermes plc Reports First Quarter 2014 Financial ResultsPrinter Friendly Version
04/23/14Alkermes to Host Conference Call to Discuss First Quarter 2014 Financial ResultsPrinter Friendly Version
04/08/14Alkermes Announces Positive Topline Results From Pivotal Phase 3 Study of Aripiprazole Lauroxil for Treatment of SchizophreniaPrinter Friendly Version
03/06/14Alkermes Announces Initiation of ALKS 5461 Pivotal Clinical Program for Treatment of Major Depressive DisorderPrinter Friendly Version
02/27/14Alkermes plc Reports Financial Results for the Periods Ended Dec. 31, 2013 and Provides Financial Expectations for 2014Printer Friendly Version
02/24/14Alkermes’ Corporate Presentation to be Webcast at the Cowen and Company 34Th Annual Health Care ConferencePrinter Friendly Version
02/20/14Alkermes to Host Conference Call to Discuss Financial Results for Periods Ended Dec. 31, 2013Printer Friendly Version
02/03/14Alkermes to Present at Two Upcoming Investor ConferencesPrinter Friendly Version
01/13/14Invesco Perpetual Funds to Make $250 Million Direct Investment in Alkermes’ Ordinary SharesPrinter Friendly Version
01/08/14Alkermes Announces Advances With Its Late-Stage CNS PipelinePrinter Friendly Version
01/07/14Alkermes’ Corporate Presentation to be Webcast at the 32nd Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version
01/06/14Alkermes Announces Notice of Allowance of U.S. Patent for a Novel Fumarate Prodrug for Multiple SclerosisPrinter Friendly Version

Other Resources

Email Alerts

Stay in Touch with Alkermes